sars cov 2 2019 ncov nucleocapsid his recombinant protein covid 19 nucleocapsid research Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Sino Biological sars cov 2 2019 ncov nucleocapsid his recombinant protein covid 19 nucleocapsid research
    Prevalence of <t>anti-SARS-CoV-2</t> IgG antibodies across study groups and validation of the results. a Left: Prevalence and 95% confidence intervals of a positive anti-SARS-CoV-2 IgG antibody test recognizing the S1 domain of the spike protein in the non-health care (NHC) control cohort, health care (HC) control cohort and immune-mediated inflammatory diseases (IMIDs) with and without cytokine inhibitors (CI); right: risk ratios and 95% confidence intervals of anti-SARS-CoV-2 IgG antibody positivity in the HC control cohort and IMIDs with and without cytokine inhibitors (CI) with the NHC control cohort as reference; b Comparison of anti- SARS-CoV-2 IgG positive (anti-S1+; N = 10) and negative (anti-S1; N = 10) samples (in Euroimmune ELISA) for reactivity in the chemi-luminescent anti- SARS-CoV-2 Spike S1/nucleocapsid IgG test (Yhlo Biotech) and anti-nucleocapsid IgG antibody ELISA (Immundiagnostik Inc). c Validation with in-house ELISA testing reactivities against 1 the S1 domain of the spike protein 2 , the receptor binding domain (RBD) of the S1 domain of the spike protein 3 , extracellular domain (ECD) of the S2 domain of the spike protein and 4 the nucleocapsid in anti- SARS-CoV-2 IgG negative ( N = 6) and positive ( N = 6) samples (in Euroimmune ELISA), COVID-19 patients with positive viral RNA test ( N = 6) and patients with endemic human coronavirus (HCoV) infection ( N = 5) in the pre- SARS-CoV-2 time.
    Sars Cov 2 2019 Ncov Nucleocapsid His Recombinant Protein Covid 19 Nucleocapsid Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov nucleocapsid his recombinant protein covid 19 nucleocapsid research/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov nucleocapsid his recombinant protein covid 19 nucleocapsid research - by Bioz Stars, 2021-06
    95/100 stars
      Buy from Supplier

    96
    Sino Biological sars cov 2 2019 ncov spike s1 s2 ecd his recombinant protein covid 19 spike research
    Sorting of T cell subsets and identification of <t>SARS-CoV-2</t> Spike- and Nucleoprotein-reactive CD4 + T cells in <t>COVID-19</t> and pre-pandemic samples. ( A ) Sorting strategy to isolate CD4 + total memory T cells and Tcm, Tem and cTfh subsets. ( B, C ) Characterization of antigen-specific T cells by CFSE dilution combined with CD25 and ICOS co-expression at day 7 following stimulation with Spike or Nucleoprotein in the presence of autologous monocytes. Negative controls of T cells cultured with monocytes alone are reported as dashed lines. Shown are data from patient P2 and from a pre-pandemic healthy donor sample (HD1).
    Sars Cov 2 2019 Ncov Spike S1 S2 Ecd His Recombinant Protein Covid 19 Spike Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike s1 s2 ecd his recombinant protein covid 19 spike research/product/Sino Biological
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike s1 s2 ecd his recombinant protein covid 19 spike research - by Bioz Stars, 2021-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    Prevalence of anti-SARS-CoV-2 IgG antibodies across study groups and validation of the results. a Left: Prevalence and 95% confidence intervals of a positive anti-SARS-CoV-2 IgG antibody test recognizing the S1 domain of the spike protein in the non-health care (NHC) control cohort, health care (HC) control cohort and immune-mediated inflammatory diseases (IMIDs) with and without cytokine inhibitors (CI); right: risk ratios and 95% confidence intervals of anti-SARS-CoV-2 IgG antibody positivity in the HC control cohort and IMIDs with and without cytokine inhibitors (CI) with the NHC control cohort as reference; b Comparison of anti- SARS-CoV-2 IgG positive (anti-S1+; N = 10) and negative (anti-S1; N = 10) samples (in Euroimmune ELISA) for reactivity in the chemi-luminescent anti- SARS-CoV-2 Spike S1/nucleocapsid IgG test (Yhlo Biotech) and anti-nucleocapsid IgG antibody ELISA (Immundiagnostik Inc). c Validation with in-house ELISA testing reactivities against 1 the S1 domain of the spike protein 2 , the receptor binding domain (RBD) of the S1 domain of the spike protein 3 , extracellular domain (ECD) of the S2 domain of the spike protein and 4 the nucleocapsid in anti- SARS-CoV-2 IgG negative ( N = 6) and positive ( N = 6) samples (in Euroimmune ELISA), COVID-19 patients with positive viral RNA test ( N = 6) and patients with endemic human coronavirus (HCoV) infection ( N = 5) in the pre- SARS-CoV-2 time.

    Journal: Nature Communications

    Article Title: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

    doi: 10.1038/s41467-020-17703-6

    Figure Lengend Snippet: Prevalence of anti-SARS-CoV-2 IgG antibodies across study groups and validation of the results. a Left: Prevalence and 95% confidence intervals of a positive anti-SARS-CoV-2 IgG antibody test recognizing the S1 domain of the spike protein in the non-health care (NHC) control cohort, health care (HC) control cohort and immune-mediated inflammatory diseases (IMIDs) with and without cytokine inhibitors (CI); right: risk ratios and 95% confidence intervals of anti-SARS-CoV-2 IgG antibody positivity in the HC control cohort and IMIDs with and without cytokine inhibitors (CI) with the NHC control cohort as reference; b Comparison of anti- SARS-CoV-2 IgG positive (anti-S1+; N = 10) and negative (anti-S1; N = 10) samples (in Euroimmune ELISA) for reactivity in the chemi-luminescent anti- SARS-CoV-2 Spike S1/nucleocapsid IgG test (Yhlo Biotech) and anti-nucleocapsid IgG antibody ELISA (Immundiagnostik Inc). c Validation with in-house ELISA testing reactivities against 1 the S1 domain of the spike protein 2 , the receptor binding domain (RBD) of the S1 domain of the spike protein 3 , extracellular domain (ECD) of the S2 domain of the spike protein and 4 the nucleocapsid in anti- SARS-CoV-2 IgG negative ( N = 6) and positive ( N = 6) samples (in Euroimmune ELISA), COVID-19 patients with positive viral RNA test ( N = 6) and patients with endemic human coronavirus (HCoV) infection ( N = 5) in the pre- SARS-CoV-2 time.

    Article Snippet: The following antigens were used: recombinant SARS-CoV-2 Spike Protein, S1 Subunit (1-Us-Tag); SARS-CoV-2 Spike S1 receptor binding domain (His-Tag) (both Sino Biological, Beijing, China); SARS-CoV-2 (2019-nCoV) Meridian Biosciences (Memphis, TX); Spike Protein (S2 ECD, His tag); SARS-CoV-2 (COVID-19) nucleocapsid protein(Sino Biological, Beijing, China).

    Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Infection

    Sequence coverage and proteotypic target peptide selection for development of a PRM assay for the SARS CoV-2 Spike protein and NP. (Top panel) Diagram of SARS CoV-2 recombinant spike glycoprotein showing the location of NTD, RBD, fusion peptide and heptad repeats 1 and 2, and the protease cleavage sites, His and Strep tags. The amino acid sequence is given below. Glycosylation sites are indicated in green. (Bottom panel) Diagram of SARS CoV-2 recombinant NP showing intrinsically disordered regions, RNA binding and dimerization regions. Phosphorylation sites (S) are indicated in yellow. Bold italics indicate sites where sequence coverage was not obtained. Peptides monitored in the spectral library are boxed, peptides selected for the final PRM assay are boxed and indicated in red text. Overall 97.1% of the spike protein and 77.2% of the NP sequence was obtained from the DDA analysis.

    Journal: Analytical Chemistry

    Article Title: Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein

    doi: 10.1021/acs.analchem.0c02288

    Figure Lengend Snippet: Sequence coverage and proteotypic target peptide selection for development of a PRM assay for the SARS CoV-2 Spike protein and NP. (Top panel) Diagram of SARS CoV-2 recombinant spike glycoprotein showing the location of NTD, RBD, fusion peptide and heptad repeats 1 and 2, and the protease cleavage sites, His and Strep tags. The amino acid sequence is given below. Glycosylation sites are indicated in green. (Bottom panel) Diagram of SARS CoV-2 recombinant NP showing intrinsically disordered regions, RNA binding and dimerization regions. Phosphorylation sites (S) are indicated in yellow. Bold italics indicate sites where sequence coverage was not obtained. Peptides monitored in the spectral library are boxed, peptides selected for the final PRM assay are boxed and indicated in red text. Overall 97.1% of the spike protein and 77.2% of the NP sequence was obtained from the DDA analysis.

    Article Snippet: SARS-CoV-2 nucleocapsid-His recombinant protein was purchased from Sino Biological (100 μg, 40588-V08B) The protein was difficult to dissolve and required treatment before S-trap preparation below with 40 μL dimethyl sulfoxide (276855—100 mL, Sigma), 126 μL 1% TFA, and 100 μL 1× S-Trap lysis buffer (5% SDS, 50 mM TEAB, pH adjusted to 7.55 using 12% phosphoric acid).

    Techniques: Sequencing, Selection, Recombinant, RNA Binding Assay

    Chromatograms and calibration curves for two best target peptides used in the PRM assay for SARS CoV-2 spike protein and nuceloprotein. The summed area under curve values for the top four transitions of each peptide were taken to generate calibration curves for quantitation. The right panels display chromatograms obtained for each of transitions shown in different colors for (A) DQVILLNK (NP) and (B) FQTLLALHR (S). Three technical replicates were run on two separate days. The chromatograms on the left of each panel show a low and high standard from the SARS CoV-2 S and NP in a mucin background. Calibration curves were constructed from the PRM data (top right) and zoomed in (bottom right) displaying mean values at the low end of the curve to show the LOD (left dotted line) and LOQ (right dotted line).

    Journal: Analytical Chemistry

    Article Title: Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein

    doi: 10.1021/acs.analchem.0c02288

    Figure Lengend Snippet: Chromatograms and calibration curves for two best target peptides used in the PRM assay for SARS CoV-2 spike protein and nuceloprotein. The summed area under curve values for the top four transitions of each peptide were taken to generate calibration curves for quantitation. The right panels display chromatograms obtained for each of transitions shown in different colors for (A) DQVILLNK (NP) and (B) FQTLLALHR (S). Three technical replicates were run on two separate days. The chromatograms on the left of each panel show a low and high standard from the SARS CoV-2 S and NP in a mucin background. Calibration curves were constructed from the PRM data (top right) and zoomed in (bottom right) displaying mean values at the low end of the curve to show the LOD (left dotted line) and LOQ (right dotted line).

    Article Snippet: SARS-CoV-2 nucleocapsid-His recombinant protein was purchased from Sino Biological (100 μg, 40588-V08B) The protein was difficult to dissolve and required treatment before S-trap preparation below with 40 μL dimethyl sulfoxide (276855—100 mL, Sigma), 126 μL 1% TFA, and 100 μL 1× S-Trap lysis buffer (5% SDS, 50 mM TEAB, pH adjusted to 7.55 using 12% phosphoric acid).

    Techniques: Quantitation Assay, Construct

    PRM assay results of mock (SARS-CoV-2 spiked) samples. Three biological replicates processed on different days and averaged from three technical replicates from each mock sample were evaluated using the calibration curves for the two best performing peptides (A) DQVILLNK and (B) FQTLLALHR. The samples represent the spiked-in amounts; low (3.125 μL) and high (12.5 μL) of inactivated SARS-CoV-2 virions into in vitro derived mucus. Tables below display the average calculated amol amounts obtained on each day along with the interday mean and % CV. The dotted line indicates the calculated LOD and the dashed line indicated the LOQ determined from the calibration curves generated for each peptide.

    Journal: Analytical Chemistry

    Article Title: Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein

    doi: 10.1021/acs.analchem.0c02288

    Figure Lengend Snippet: PRM assay results of mock (SARS-CoV-2 spiked) samples. Three biological replicates processed on different days and averaged from three technical replicates from each mock sample were evaluated using the calibration curves for the two best performing peptides (A) DQVILLNK and (B) FQTLLALHR. The samples represent the spiked-in amounts; low (3.125 μL) and high (12.5 μL) of inactivated SARS-CoV-2 virions into in vitro derived mucus. Tables below display the average calculated amol amounts obtained on each day along with the interday mean and % CV. The dotted line indicates the calculated LOD and the dashed line indicated the LOQ determined from the calibration curves generated for each peptide.

    Article Snippet: SARS-CoV-2 nucleocapsid-His recombinant protein was purchased from Sino Biological (100 μg, 40588-V08B) The protein was difficult to dissolve and required treatment before S-trap preparation below with 40 μL dimethyl sulfoxide (276855—100 mL, Sigma), 126 μL 1% TFA, and 100 μL 1× S-Trap lysis buffer (5% SDS, 50 mM TEAB, pH adjusted to 7.55 using 12% phosphoric acid).

    Techniques: In Vitro, Derivative Assay, Generated

    Schematic of the workflow used to develop a PRM assay for the detection and quantitation of SARS-CoV-2 spike and NP (A) PRM assay development was performed using recombinant SARS CoV-2 spike protein and NP. Proteotypic target peptides/transitions were selected to generate a spectral library in Skyline. (B) PRM assay was then used to quantitate the SARS-CoV-2 protein levels in a mock sample that was created by adding an inactivated virus sample to in vitro derived mucus.

    Journal: Analytical Chemistry

    Article Title: Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein

    doi: 10.1021/acs.analchem.0c02288

    Figure Lengend Snippet: Schematic of the workflow used to develop a PRM assay for the detection and quantitation of SARS-CoV-2 spike and NP (A) PRM assay development was performed using recombinant SARS CoV-2 spike protein and NP. Proteotypic target peptides/transitions were selected to generate a spectral library in Skyline. (B) PRM assay was then used to quantitate the SARS-CoV-2 protein levels in a mock sample that was created by adding an inactivated virus sample to in vitro derived mucus.

    Article Snippet: SARS-CoV-2 nucleocapsid-His recombinant protein was purchased from Sino Biological (100 μg, 40588-V08B) The protein was difficult to dissolve and required treatment before S-trap preparation below with 40 μL dimethyl sulfoxide (276855—100 mL, Sigma), 126 μL 1% TFA, and 100 μL 1× S-Trap lysis buffer (5% SDS, 50 mM TEAB, pH adjusted to 7.55 using 12% phosphoric acid).

    Techniques: Quantitation Assay, Recombinant, In Vitro, Derivative Assay

    Sorting of T cell subsets and identification of SARS-CoV-2 Spike- and Nucleoprotein-reactive CD4 + T cells in COVID-19 and pre-pandemic samples. ( A ) Sorting strategy to isolate CD4 + total memory T cells and Tcm, Tem and cTfh subsets. ( B, C ) Characterization of antigen-specific T cells by CFSE dilution combined with CD25 and ICOS co-expression at day 7 following stimulation with Spike or Nucleoprotein in the presence of autologous monocytes. Negative controls of T cells cultured with monocytes alone are reported as dashed lines. Shown are data from patient P2 and from a pre-pandemic healthy donor sample (HD1).

    Journal: bioRxiv

    Article Title: Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2

    doi: 10.1101/2021.03.23.436642

    Figure Lengend Snippet: Sorting of T cell subsets and identification of SARS-CoV-2 Spike- and Nucleoprotein-reactive CD4 + T cells in COVID-19 and pre-pandemic samples. ( A ) Sorting strategy to isolate CD4 + total memory T cells and Tcm, Tem and cTfh subsets. ( B, C ) Characterization of antigen-specific T cells by CFSE dilution combined with CD25 and ICOS co-expression at day 7 following stimulation with Spike or Nucleoprotein in the presence of autologous monocytes. Negative controls of T cells cultured with monocytes alone are reported as dashed lines. Shown are data from patient P2 and from a pre-pandemic healthy donor sample (HD1).

    Article Snippet: 40589-V08B1), SARS-CoV-2 (2019-nCoV) Nucleocapsid protein (cat.no.

    Techniques: Transmission Electron Microscopy, Expressing, Cell Culture